Photo from wikipedia
Abstract Metabolic syndrome (MetS) in patients with schizophrenia occurs 2–3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In… Click to show full abstract
Abstract Metabolic syndrome (MetS) in patients with schizophrenia occurs 2–3 times more frequently than in the general population. Antipsychotic medication is a primary risk factor for patients with MetS. In particular, the widely used second-generation antipsychotics can affect glucose and lipid metabolism and can induce insulin resistance and other metabolic abnormalities through various receptors. Notably, the metabolic risks of various antipsychotics may differ because of their different pharmacological affinity to MetS-related receptors. Several previous studies have shown that switching from high to low metabolic risk antipsychotics may improve patients’ metabolic parameters. The current review aims to discuss the strategies for switching antipsychotic medications and the impact on metabolic abnormalities in patients with schizophrenia.
Journal Title: Neuropsychiatric Disease and Treatment
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!